Hypoport SE Financial Results 9M 2026 | EBIT +27% & Outlook

In this seat11a Financial Results presentation, Ronald Slabke, CEO of Hypoport SE, presents the company’s third-quarter and nine-month 2026 financial performance, including Group revenue, gross profit, operating earnings, mortgage finance volumes, digital platform developments and the company’s full-year outlook.Hypoport SE, a German technology company specialising in digital platforms for mortgage finance, real estate, housing-sector financing and insurance, continued to achieve profitable growth despite subdued market conditions during the first nine months of 2026. The company’s platform-based business model and market-share gains supported revenue development and operating profitability across its three business segments.Hypoport 9M 2026 Revenue, Gross Profit and EBITFor 9M 2026, Group revenue increased by 5% to €480 million, compared with €459 million in the previous year. Gross profit rose by 5% to €207 million, while EBITDA increased by 11% to €56 million. EBIT improved by 27% to €30 million, compared with €24 million in 9M 2025, lifting the EBIT margin on gross profit to approximately 15%.Europace, Finmas and Genopace Mortgage Finance VolumesThe Real Estate & Mortgage Platforms segment remained the largest contributor to Group profitability. Segment revenue increased by 4% to €368 million, gross profit rose by 6% to €129 million and EBIT advanced by 10% to €36 million. Mortgage financing volumes through Europace remained broadly stable at €57.3 billion, while regional banking platforms continued to gain market share. Finmas increased mortgage volume by 13% to €9.9 billion, and Genopace recorded growth of 7% to €15.8 billion. Dr. Klein Privatkunden increased its brokered mortgage financing volume by 3% to €6.1 billion.Hypoport also reported improving contributions from its property valuation business. VALUE AG benefited from growing demand for valuation services, recorded only minimal losses during the first nine months and reached break-even in Q3 2026. The company continues to identify opportunities for further market-share gains in mortgage finance, particularly among regional banks, while the broader German housing market remains affected by financing costs and subdued transaction activity.WOWIPORT Growth and Financing PlatformsIn the Financing Platforms segment, revenue increased by 3% to €61 million, while gross profit rose by 2% to €51 million. EBIT declined by 6% to €3.6 million, reflecting continued investment in digital platforms and challenging conditions in housing-sector finance, corporate lending and personal loans. The WOWIPORT SaaS property management platform achieved particularly strong growth, with the number of residential units under contract increasing by 31% to approximately 801,000. Rental deposits managed through WOWIAccount rose by 9% to €1.4 billion, while an alliance with Aareal Bank expanded the company’s activities in housing-sector financial services...▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this seat11a Financial Results presentation, the CFO of ZEAL Network SE reviews the first nine months of 2026, including lottery and games performance, SevenCanyon’s contribution and the updated full-year outlook.Group revenue increased 22.2% to €198.8 million. Reported EBITDA rose 8.6% to €58.7 million, while net profit declined 4.9% to €32.2 million. The prior-year period included a €4.1 million positive one-off deferred tax effect.• Lottery revenue rose 15.7% to €170.8 million, with €915.1 million in billings and an 18.3% gross margin.• ZEAL registered 1.007 million new lottery customers, up 15%.• Games revenue increased 17.7% to €12.1 million as monthly active users increased 27%.• SevenCanyon contributed €10.5 million in revenue and €1.4 million in EBITDA from July 9 through September 30.• ZEAL raised 2026 revenue guidance to €270–280 million following the acquisition. EBITDA guidance remains €70–75 million.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this seat11a Financial Results presentation, Jörg Peters, Head of Investor Relations at Amadeus Fire Group, presents the company's Q3 and 9M 2026 results, including revenue development, operating profitability, segment performance and the updated FY 2026 outlook.• 9M 2026 Group revenue declined 5.7% to €261.5 million, while operating EBITA rose 20.0% to €11.7 million (margin 4.5%).• Q3 2026 revenue reached €89.8 million (-0.9%); operating EBITA increased about 148% to €8.2 million, a 9.1% margin. EPS returned to €0.43.• Personnel Services revenue fell 15.6% to €135.8 million in 9M amid a weak German recruitment market.• The Training segment grew revenue 8.1% to €125.9 million and returned to profitability with €7.5 million operating EBITA.• FY 2026 guidance confirmed and narrowed: revenue €350–355 million, operating EBITA €17–20 million.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this seat11a Financial Results presentation, Felix Strohbichler, CFO of PALFINGER AG, presents the company’s results for the first nine months of 2026. The presentation covers revenue growth, operating profitability, portfolio changes, Russia-related accounting effects, cash flow and the full-year outlook.PALFINGER Q1-Q3 2026 Results: Revenue and Operating EarningsPALFINGER reported revenue of €1,616.7 million, an increase of 3.9% compared with €1,556.3 million in the adjusted prior-year period. EBITDA declined 1.9% to €190.4 million, while EBIT decreased 5.8% to €120.7 million. The EBIT margin reached 7.5%, compared with 8.2% a year earlier.Revenue, EBITDA and EBIT exclude CIS and Tail Lifts. Prior-year comparatives are adjusted in accordance with IFRS 5. These figures represent cumulative nine-month performance rather than standalone third-quarter results.The consolidated net result was a loss of €61.5 million, compared with a profit of €72.4 million in the prior-year period. Discontinued operations and Russia-related accounting effects influenced the consolidated bottom line.Russian Operations: Write-Down and Planned DeconsolidationPALFINGER initiated a legal structure to strengthen the ring-fencing of its Russian operations and prepare their deconsolidation. The company continues to own the Russian entities.The presentation identifies an approximately €135 million write-down in Q3 2026, including €15 million attributable to minority interests. This affects net income through discontinued operations but has no effect on EBIT or cash flow.Upon future deconsolidation, PALFINGER indicates an additional approximately €45 million effect from recycling the currency translation reserve into profit and loss. This would affect net income without affecting equity.Potential Sale of the Tail & Passenger Lift BusinessPALFINGER signed a binding pre-agreement for the potential sale of its Tail & Passenger Lift business to a strategic investor. The transaction has not yet been completed. Due diligence, final negotiations and merger control approval remain pending.Closing is expected in Q4 2026 or Q1 2027. The business is classified as held for sale and reported below EBIT as discontinued operations. A single-digit million write-off is expected to affect net income rather than EBIT, with the final amount depending on due diligence findings and closing accounts.Regional Market DevelopmentsEMEA: Stable Markets with Regional DifferencesEMEA accounted for 53.6% of reported revenue. European market conditions remained stable overall, although Germany and Austria continued to be weak. Northern and Southern Europe showed solid demand.North America: Record Loader Crane SalesNorth America represented 23.5% of revenue. Loader Cranes achieved record sales, supported in part by data center investments. Other product lines continued to face weak demand, while truck registrations showed initial signs of recovery.Marine, Latin America and Asia-PacificMarine contributed 14.0% of revenue, supported by strong developments in marine and wind cranes, as well as Cruise & Governmental Business. Services declined amid escalation in the Middle East....▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Wacker Chemie AG Financial Results 9M 2026 Earnings Recovery & OutlookWacker Chemie AG 9M 2026: Key TakeawaysIn this seat11a Financial Results presentation, Joerg Hoffmann, CFA, Head of Investor Relations, presents Wacker Chemie AG’s Q3 2026 results, covering revenue growth, earnings, cash flow, segment performance and the updated full-year outlook. The quarter saw higher sales and profitability, supported by pricing, volume and mix improvements, and the PACE cost and efficiency program.WACKER Q3 2026 Results: Sales and Earnings GrowthWACKER generated sales of €1.466 billion in the third quarter of 2026, an increase of 9% compared with €1.340 billion a year earlier. Pricing contributed 6% to sales growth, volume and mix contributed 2%, and currency effects added 1%.Reported EBITDA increased 94% to €217 million, with an EBITDA margin of 14.8%, compared with 8.3% in Q3 2025. Reported EBITDA included €35 million in special income from the cancellation of a solar contract. Operating EBITDA reached €182 million, up 63% year over year.EBIT improved to €103 million from a loss of €20 million. Net income for the period reached €87 million, compared with a loss of €82 million, while earnings per share rose to €1.68 from minus €1.73.PACE Cost Savings and REFOCUS StrategyThe PACE cost and efficiency program contributed more than €60 million to Q3 2026 performance. WACKER targets more than €300 million in savings in 2028. These measures supported operating earnings alongside improvements in volume and product mix.The presentation also outlines REFOCUS, WACKER’s strategic framework for growth, profitability and return on capital employed. Structural financial ambitions include growth above GDP, an EBITDA margin of 15%, plus or minus two percentage points, and ROCE above 10% and above the cost of capital. These are structural ambitions rather than guidance for 2026.Segment Performance: Silicones, Polymers, Biosolutions and PolysiliconWACKER Silicones: Pricing, Mix and Cost PerformanceSilicones sales increased 8% to €729 million. EBITDA rose 35% to €116 million, supported by pricing, an improved product mix and the PACE program. The reported EBITDA margin was 16.0%.WACKER Polymers: Higher Sales and EBITDAPolymers sales rose 11% to €381 million as prices followed raw material inflation. EBITDA increased 58% to €75 million, with a margin of 19.6%. Cost savings from PACE supported the result, which also included effects from raw material volatility.WACKER Biosolutions: Growth in BioPharma and Life Science ChemicalsBiosolutions generated sales of €100 million, up 8% year over year, while EBITDA remained at €8 million. BioPharma and Life Science Chemicals developed positively, with commercial excellence a focus for filling available capacity.WACKER Polysilicon: Semiconductor Growth and Solar UncertaintyPolysilicon sales increased 14% to €225 million. EBITDA reached €44 million, including the €35 million solar contract cancellation income. Higher semiconductor volumes and cost performance supported earnings, while the solar business continued to face pressure and trade-policy uncertainty....▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Valbiotis Deep Dive: Key TakeawaysIn this seat11a Deep Dive, Sébastien Peltier, Co-Founder and Chairman of the Management Board of Valbiotis, presents the French listed life sciences company’s transformation from clinical research and biotechnology licensing to commercial growth in natural health products for cardiometabolic health.The presentation covers Valbiotis’ business model, TOTUM-63 clinical validation, REVERSE-IT study results, Nature Communications publication, H1 2026 sales performance, French pharmacy distribution, Valbiotis PRO® product portfolio, China joint venture, Middle East partnerships and international expansion strategy.Valbiotis Scientific Research and TOTUM-63In July 2026, the results of Valbiotis’ REVERSE-IT clinical study involving TOTUM•63 were published in Nature Communications, a leading peer-reviewed scientific journal.The international, randomised, placebo-controlled study involved 636 participants with elevated blood glucose across 52 clinical centres in Europe.Valbiotis’ scientific network includes collaborations with INSERM, INRAE, Leiden University, Vanderbilt University and other research institutions. Since 2016, its research has been selected more than 60 times at scientific congresses, including the American Diabetes Association and American Heart Association.Valbiotis Business Model: From Nestlé Health Science to Independent CommercialisationFounded in 2014, Valbiotis originally developed clinically validated natural health solutions for licensing to international healthcare companies.In 2020, the company entered into a partnership with Nestlé Health Science for TOTUM•63, including a CHF 5 million upfront payment, potential milestone payments exceeding CHF 60 million and future royalties.Following the end of the partnership in mid-2024, Valbiotis changed its business model to develop and commercialise its own brand in France and international markets.Valbiotis H1 2026 Revenue and Pharmacy GrowthThe company’s French commercial activities have expanded substantially:H1 2026 French revenue: €0.8 million, compared with €0.3 million in H1 2025 and €0.04 million in H1 2024.599 partner pharmacies as of 30 June 2026, compared with 262 at the end of 2024.25 pharmacy group agreements covering nearly 4,800 pharmacies in France....Valbiotis PRO® Product Portfolio and Commercial StrategyThe launch of Valbiotis PRO® Liver completes the company’s range of four products with clinically tested efficacy.Its French commercial organisation includes three regional directors and 19 medical sales representatives, supporting pharmacy penetration, healthcare professional engagement and increasing sales per pharmacy.Valbiotis China and Middle East ExpansionValbiotis has signed three international agreements across two continents.Its Chinese joint venture is operational, with initial sales expected by the end of 2026. In the Middle East, product registrations are expected during H1 2027, supporting subsequent market entry.The company is also evaluating new distribution channels and additional countries as it pursues its ambition to become an international leader in natural health products for cardiometabolic health.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Valbiotis Elevator Pitch: Key TakeawaysIn this seat11a Elevator Pitch, Sébastien Peltier, Co-Founder and Chairman of the Management Board of Valbiotis, introduces the company’s business model, clinically tested natural health products, commercial growth strategy and international expansion plans.Valbiotis Business Model and Commercialisation StrategyFounded in 2014, Valbiotis is a French life sciences company focused on natural solutions for cardiometabolic health. After more than a decade of scientific research and over €60 million invested in research and development, the company has transitioned into commercialisation. Its activities combine scientific product development, intellectual property, branded natural health products and distribution through pharmacies, e-commerce and international partners.Valbiotis PRO® and Valbiotis PLUS® Product PortfolioValbiotis operates through two complementary product ranges. Valbiotis PRO® comprises four clinically tested products addressing cholesterol, blood glucose, blood pressure and fatty liver. These include Lipidrive®, TOTUM•63, Tensodrive® and Steadrive®. Valbiotis PLUS® extends the portfolio into everyday health, including sleep, fatigue, immunity, vitality and menopause-related concerns, as well as combined health programs.Clinical Studies, Scientific Validation and Intellectual PropertyScientific validation represents a central part of the company’s positioning. Its four Valbiotis PRO® products have been evaluated across 12 clinical studies involving 1,551 participants, supported by 17 international peer-reviewed publications, including one in Nature Communications. Valbiotis also holds patents covering up to 58 countries, providing intellectual property protection for its innovations.Cardiometabolic Health Market and Growth OpportunitiesThe addressable market is substantial. Cardiometabolic imbalances affect billions of adults worldwide, including people experiencing elevated cholesterol, impaired glucose regulation, high blood pressure and metabolic dysfunction-associated fatty liver disease. Valbiotis focuses on the early stages of these conditions, supported by growing consumer interest in natural solutions and plant-based health products.French Pharmacy Distribution, E-Commerce and H1 2026 Sales GrowthIn France, the company is developing a commercial model combining pharmacy distribution and direct online sales. By 30 June 2026, Valbiotis had established partnerships with 599 pharmacies, representing approximately 26% growth over six months. Its in-house medical sales force supports healthcare professionals and pharmacy partners, while e-commerce provides a complementary direct-to-consumer channel. According to management, French sales increased approximately 130% during H1 2026.International Expansion in China, Asia and the Middle EastInternational expansion is based on a capital-light partnership strategy. Valbiotis currently has agreements covering 12 countries and markets across Asia and the Middle East. Its Chinese joint venture provides access to eight Asian markets, while distribution partners cover Saudi Arabia, Lebanon, Iraq and Qatar. Initial sales in China are expected by the end of 2026, with product registrations in the Middle East anticipated during H1 2027...▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

WACKER Chemie AG 2026 Capital Markets Day Deep DiveIn this seat11a Deep Dive, Joerg Hoffmann, CFA, Senior Vice President Investor Relations at WACKER Chemie AG, presents a concise recap of the company’s 2026 Capital Markets Day and explains how its new REFOCUS strategy is intended to strengthen profitability, cash generation and returns.WACKER’s Four Business SegmentsWACKER operates through four segments: Silicones, Polymers, Biosolutions and Polysilicon. Each combines differentiated technology with leading or highly specialised market positions. In 2025, the group generated sales of approximately €5.5 billion, serving markets ranging from construction and coatings to electronics, mobility, energy, healthcare and wellbeing.REFOCUS Strategy and Capital AllocationThe central change introduced through REFOCUS is that WACKER will no longer manage every business according to the same strategic priorities. Individual portfolio units are assigned one of four roles: Accelerate Growth, Optimise Return, Maximise Cash or Turnaround. These roles define the relevant performance indicators and determine how resources and capital are allocated.Accelerate Growth Through Innovation and CommercialisationIn its Accelerate Growth businesses, WACKER is directing innovation towards markets in which the company believes it has a clear competitive advantage. Examples include battery safety, thermal management and sensor protection for semiconductor applications, optical encapsulants for Mini- and Micro-LEDs, transdermal active-delivery patches and plant-based taurine. The emphasis is on accelerating commercialisation rather than simply increasing research expenditure.Optimise Return Across Established BusinessesThe Optimise Return portfolio includes established businesses in which WACKER already holds strong market positions. Priorities include automation and yield improvements in semiconductor-grade polysilicon, pricing discipline in dispersible polymer powders and greater flexibility in specialty silicones production.Tailored Strategies for Silicones, Polymers, Biosolutions and PolysiliconEach of WACKER’s four segments consequently receives a tailored strategy. Silicones is focused on asset-light downstream expansion, while Polymers combines market and technology leadership with cost, capital and portfolio discipline. Biosolutions is concentrating on technology-led growth and stronger commercial execution. Polysilicon aims to extend its global leadership in semiconductor applications while maintaining strategic optionality in the US solar market.PACE Programme and Structural Cost SavingsWACKER enters this strategic phase with strong liquidity, low leverage and a high equity ratio. Its profitability ambitions are supported by selective growth, improved portfolio mix and structural cost measures. The PACE programme is expected to generate more than €300 million of annual gross cost savings by 2028, with more than half retained in EBITDA.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Solutiance AG Elevator Pitch PresentationIn this Elevator Pitch on seat11a, Jonas Enderlein, CEO of Solutiance AG, explains how the company combines technology and physical services to digitalise facility management for owners and operators of real estate portfolios.Digitalising Traditional Facility ManagementSolutiance addresses a structural weakness in traditional facility management: services and software are typically separated. Conventional service providers perform the required work on site, but analogue processes can result in inefficient workflows, inconsistent service quality and insufficient data. Standalone software can provide a better technological foundation, but requires implementation, training and upfront investment while still depending on users to maintain complete and accurate information.Smartsourcing Model and Facility Scanner PlatformSolutiance combines these two worlds through its Smartsourcing model. Its own employees and external service providers work within digital processes supported by Solutiance’s technology and, increasingly, artificial intelligence. At the centre is the company’s Facility Scanner platform, which coordinates workflows and captures the information generated during service delivery.Digital Twin Technology for Real Estate PortfoliosAs work is performed, Solutiance creates a digital twin of the building for the relevant trade. Property owners therefore receive both the physical service and a continuously developing digital data foundation. This allows customers to monitor service delivery, access asset information and make decisions based on portfolio data rather than relying primarily on manual reporting or incomplete information.Recurring Revenue and Subscription-Based ServicesThe commercial model combines an initial onboarding fee for creating the digital twin with subsequent subscription-based services. According to management, this means that the majority of Solutiance’s revenue is either recurring or returning. Every service performed also leaves a digital trace within Facility Scanner, potentially strengthening the data foundation and customer relationship over time.Scalable Technology Platform and Artificial IntelligenceThe model is designed to be highly scalable. As Solutiance adds services, it can use the existing technology infrastructure, digital processes, property data and service network across a broader part of the customer’s building portfolio. AI provides another potential efficiency lever as more workflows become automated or digitally supported.Long-Term Vision for Full-Service Property CoverageThe company’s longer-term vision is particularly important to the equity story: Solutiance intends to continuously expand its service portfolio until it can provide full-service property coverage, effectively enabling customers to operate complete buildings through Solutiance’s technology and service ecosystem.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

BRAIN Biotech AG 9M 2025/26: Key TakeawaysIn this Financial Results presentation on seat11a, Michael Schneiders, CFO of BRAIN Biotech AG, presents the company’s 9M FY 2025/26 Financial Results and discusses the performance of BRAINBiocatalysts and BRAINBioIncubator, profitability, cash flow, financing, the upcoming CEO transition and the updated full-year outlook.9M FY 2025/26 Revenue and Segment PerformanceBRAIN Biotech generated revenue of €34.6 million during the first nine months of FY 2025/26, representing a decline of 10.5% year-on-year. The development primarily reflects weaker performance in BRAINBiocatalysts, where revenue declined 13.3% to €30.8 million. BRAINBioIncubator developed in the opposite direction, increasing revenue 21% to €3.9 million as the company continued to realise value from its innovation portfolio.BRAINBiocatalysts and Enzyme Business DevelopmentDuring Q3, BRAINBiocatalysts revenue was sequentially stable compared with Q2 but remained below the prior-year period. Management attributes the weaker development to a high comparison base, subdued demand for baking enzymes and initial operational challenges at the new Netherlands production facility. The enzyme-related contract research business, however, remained solid and is expected to continue performing well through the remainder of the financial year.Adjusted EBITDA and BRAINBioIncubator MilestonesAdjusted Group EBITDA amounted to minus €0.7 million for the nine-month period. Management continues to focus on cost control, including lower headcount, while BRAINBioIncubator milestone income is increasingly contributing to Group performance. The BioIncubator recorded a €1 million Pharvaris-related milestone during the first nine months, with another €1 million expected to be recognised in Q4. The FDA acceptance of the NDA for deucrictibant represents another important development within the portfolio.Financing, Cash Flow and Netherlands Production InvestmentThe Group has also strengthened its financing position. BRAIN secured a €9 million revolving credit line, while an additional €11.51 million Royalty Pharma milestone was received in Q4. Operating cash flow improved substantially year-on-year to minus €3.6 million, while investment in the new Netherlands production site was largely completed during Q3.CEO Transition to Dr. Sven K. WeberBRAIN is simultaneously preparing for a management transition. Dr. Sven K. Weber will become CEO on 1 October 2026, succeeding Adriaan Moelker. Weber brings significant experience in enzymes and will take over as BRAIN continues to pursue its long-term strategy of profitable specialty-enzyme growth and its ambition to become one of the world’s top-ten global enzyme companies.Updated FY 2025/26 GuidanceFollowing the weaker development of BRAINBiocatalysts, management adjusted its FY 2025/26 segment guidance. Biocatalysts revenue is now expected to be below the previous financial year’s level and the adjusted EBITDA margin below the previously anticipated level of around 10%. Conversely, BRAINBioIncubator guidance was raised, with revenue now expected at approximately €6 million and adjusted EBITDA above €1 million. Adjusted Group EBITDA is still expected to be around break-even for the full year.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.